Last year's downturn hit growth stocks especially hard, but many growth-oriented corporations performed impressively regardless. Two companies that belong to this group are Novo Nordisk (NYSE: NVO) and (NASDAQ: MELI). These stocks' performances over the past year haven't been flukes; both companies have excellent prospects and could deliver solid financial results and outsized returns in the next decade. Let's look closer at what makes Novo Nordisk and MercadoLibre such great buys.

NVO data by YCharts.

Novo Nordisk is a leading Denmark-based drugmaker. Like many of its peers, the company should benefit from increased spending on prescription medicines we are likely to see in the next decade and beyond due to an aging population. Novo Nordisk specializes in diabetes care, an area with an increasing need for therapy options. 

Continue reading

Source Fool.com